MOB2 and ovarian carcinoma: Our findings together with publicly available cell line profiling data [88] would suggest that ovarian cancer cells display a link between MOB2 mRNA levels and sensitivity to PARP inhibition and a standard genotoxic therapeutic agent, such as cisplatin.